Chan, Jeffrey S. K., Tang, Pias, Hui, Jeremy M. Ho, Lee, Yan H. A., Dee, Edward C., Ng, Kenrick, Liu, Kang, Tse, Gary, Ng, Chi Fai (2022) Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis. The Prostate, 82 (15). pp. 1477-1480. ISSN 0270-4137. E-ISSN 1097-0045. (doi:10.1002/pros.24423) (KAR id:98710)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
|
|
Download this file (PDF/495kB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1002/pros.24423 |
Abstract
Background
Although androgen deprivation therapy has known cardiovascular risks, it is unclear if its duration is related to cardiovascular risks. This study thus aimed to investigate the associations between gonadotrophin-releasing hormone (GnRH) agonist use duration and cardiovascular risks.
Methods
This retrospective cohort study included adult patients with prostate cancer receiving GnRH agonists in Hong Kong during 1999–2021. Patients who switched to GnRH antagonists, underwent bilateral orchidectomy, had <6 months of GnRH agonist, prior myocardial infarction (MI), or prior stroke was excluded. All patients were followed up until September 2021 for a composite endpoint of MI and stroke. Multivariable competing-risk regression using the Fine-Gray subdistribution model was used, with mortality from any cause as the competing event.
Results
In total, 4038 patients were analyzed (median age 74.9 years old, interquartile range (IQR) 68.7–80.8 years old). Over a median follow-up of 4.1 years (IQR 2.1–7.5 years), longer GnRH agonists use was associated with higher risk of the endpoint (sub-hazard ratio per year 1.04 [1.01–1.06], p = 0.001), with those using GnRH agonists for ≥2 years having an estimated 23% increase in the sub-hazard of the endpoint (sub-hazard ratio 1.23 [1.04–1.46], p = 0.017).
Conclusion
Longer GnRH agonist use may be associated with greater cardiovascular risks.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1002/pros.24423 |
Uncontrolled keywords: | androgen deprivation therapy; cardio‐oncology; cohort; prostate cancer |
Subjects: | R Medicine > R Medicine (General) |
Divisions: | Divisions > Division of Natural Sciences > Kent and Medway Medical School |
Funders: | University of Kent (https://ror.org/00xkeyj56) |
Depositing User: | Manfred Gschwandtner |
Date Deposited: | 05 Dec 2022 18:14 UTC |
Last Modified: | 05 Nov 2024 13:04 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/98710 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):